Journal of the Egyptian Nat. Cancer Inst., Vol. 20, No. 1, March: 10-16, 2008
|
|
- Emerald Hodges
- 5 years ago
- Views:
Transcription
1 Journal of the Egyptian Nat. Cancer Inst., Vol. 20, No. 1, March: 10-16, 2008 Prospective Phase II Study of Brachytherapy Boost as a Component of Neo-Adjuvant Chemotherapy and External Beam Radiation Therapy in Locally Advanced Rectal Cancer MOHAMED E. EL-SAYED, M.D.* and ZEINAB H. EL-TAHER, Ph.D.** The Departments of Radiation Oncology* and Medical Physics**, King Abdul-Aziz University Hospital, Faculty of Medicine, Jeddah Kingdom of Saudi Arabia. ABSTRACT Purpose: The aim of the current study is to assess the response rate and toxicity profile in patients with locally advanced rectal cancer using brachytherapy (BT) boost following external beam radiotherapy (EBRT), concomitant with chemotherapy as a component of the neoadjuvant treatment. Patients and Methods: This is a prospective phase II study of neoadjuvant chemo-radiation therapy for patients with locally advanced rectal cancer who presented to the department of radiation oncology, King Abdul-Aziz University Hospital, Jeddah, Kingdom of Saudi Arabia. Seventeen patients had been included in the study. Radiation therapy was given as: phase I, 45 Gy/25 fractions/5 weeks of EBRT, followed by brachytherapy boost (within one week after the end of EBRT) using high dose rate iridium 192 (Ir 192 ) aiming at 800cGy given in 2 fractions (each 400 cgy) separated by 1 week. All patients received the same concomitant chemotherapy in the form of Capecitabine and Oxaliplatin. The clinical and pathological response rates, together with the toxicity profile were assessed. Results: Seventeen patients had been studied; the majority (; 82%) were males, while 3 only (18%) were females, their mean age was 57.4 years. All patients had low anterior resection (LAR). The clinical response rate, assessed by digital rectal examination ± endoscopy examination 4 weeks after the end of EBRT and BT, revealed that complete clinical response (ccr) was noted in 3 patients (18%), clinical partial response (cpr) in patients (82%); while the pathological response rate was: complete pathological response (pcr) in 8 patients (47%), pathological partial response (ppr) in 9 patients (53%). The toxicity profile showed that grade III radiation proctitis was seen in one patient (6%), grade III dermatitis in 2 (12%), while no patients developed grade III cystitis. For Correspondence: Dr Mohamed Ezzat Abbas El Sayed King Abdul-Aziz University Hospital(KAUH) Jeddah, Kingdom of Saudi Arabia, drmezzat@yahoo.com chemotherapy toxicities, three patients (18%) developed grade III nausea and/or vomiting, 2 (12%) developed grade III diarrhea. Conclusion: The use of high dose rate brachytherapy as a boost in the neoadjuvant chemotherapy and radiation therapy setting in locally advanced rectal cancer is an acceptable modality with an appreciable clinical and pathological response rates as well as an acceptable toxicity profile. Key Words: Rectal cancer Neoadjuvant chemotherapy and radiation therapy Brachytherapy. INTRODUCTION In Saudi Arabia colorectal cancer is considered the second most common type of malignancy according to the Cancer Incidence Report of Saudi Arabia for the year 2004 [1]. Abdominoperineal resection (APR) has been considered to be the standard operation for lower rectal tumors with a distal edge up to 6 cm from the anal verge. Although it results in excellent local control and survival, the APR entails a permanent colostomy and a high incidence of sexual and urinary dysfunction. So, for patients with larger or more invasive tumors, neoadjuvant radiation therapy and chemoradiotherapy have been utilized to promote tumor regression in an attempt to convert a planned APR to a sphincter-sparing surgical procedure [2-5]. Neoadjuvant chemoradiation therapy in rectal cancer resulted in a high sphincter preservation rate from 41 to 95 percent, averaging 68 percent [6-13]. The aim of the current study is to assess the efficacy of barchytherapy boost 10
2 Prospective Phase II Study of Brachytherapy Boost after external beam radiation therapy concomitant with chemotherapy in terms of clinical and pathological response rates, as well as toxicity profile of both combined modalities in addition to brachytherapy. PATIENTS AND METHODS The study was conducted in the department of radiation oncology, King Abdul-Aziz University Hospital, Jeddah, Kingdom of Saudi Arabia, whereby seventeen patients with locally advanced rectal cancer referred for neoadjuvant chemoradiation therapy before definitive surgery had been evaluated. Patients involved in the study included those diagnosed between May 2006 and June 2007 (inclusive). This is a prospective phase II study done on patients with locally advanced rectal cancer who should fulfill the following inclusion criteria: pathologically proven rectal carcinoma; locally advanced (T3, or T4) lesions, with no evidence of distant metastases as proved by CT scan chest abdomen and pelvis, and bone scan before the start of treatment. Patients should be able to sign an informed consent. Tumor (T) and lymph node (N) stages were identified by rectal MRI or trans- rectal ultrasound. Baseline hematological, renal and electrolyte profiles should be within normal range to start chemotherapy. Exclusion criteria included patients with unproved pathological diagnosis of rectal cancer, patients with metastatic disease at presentation, patients with history of previous pelvic irradiation, or patients who were involved in other clinical trials. All patients received neoadjuvant chemotherapy during the course of irradiation consisting of Oxaliplatin 50 mg/m 2 intravenous (IV) given on days 1,8,22,29 and Capecitabine 825 mg/m 2 PO BID daily from day one to day, followed by 1 week rest and resumed at day 22 for 2 weeks. CT planning for all patients was done in the treatment position (prone) for phase I (whole pelvis) and phase II (brachytherapy boost to rectum). Radiation therapy was given in phase I as whole pelvic irradiation, aiming at 45 Gy/ 25 fractions/5 weeks given as daily treatments, for 5 days per week and two days rest. Each radiation fraction dose was 180cGy using a 11 linear accelerator with 3 fields; one direct posterior and two lateral fields. The energy used was 6MV in the posterior field and 18 MV in the lateral fields. Patients were treated in the prone position with full bladder to reduce small bowel toxicity. After phase I (EBRT); patients were assessed clinically (by digital rectal examination) before phase 2, which entailed delivering brachytherapy within one week after the end of EBRT using an iridium 192 (Ir 192 ) high dose rate source inserted as remote after loading in a rectal cylinder applicator given as an outpatient procedure once per week for 2 fractions (each is 400cGy) for a total of 800cGy. The dose prescription would be at 0.5 cm from the applicator surface taking care to block the uninvolved areas with lead blocks mounted in the applicator cylinder. The upper and lower margins were of the treatment length usually selected to cover the tumor and 2 cm above and below the tumor edge with every attempt to spare the anal verge. During the brachytherapy procedure, the patient lies in the prone position on the table, lidocaine gel 2% for mucous membrane with xylocaine gel were introduced around the anus and for a short distance inside the rectum to facilitate the entrance of the applicator. Examination was done to asses the extent of the lesion. The applicator was introduced in the rectum through the anus with the predetermined length and fixed to the table through the fixation arm to prevent movement of the patient during the procedure. The connected transfer tube was introduced into the tandem of the applicator and connected to the HDR machine (Figs. 1-6). We have two diameters of the rectal cylinder 2.6 and 3 cm each one with two lengths, 6 cm and 10 cm, to accommodate the tumor with acceptable safety margins. Computerized planning was then done with determination of the dwell time and position of the source according to the treatment length using the Brachy Vision V planning system. Acute reactions from radiation therapy were recorded according to the Radiation Therapy Oncology Group (RTOG) toxicity criteria [] as maximal reported reactions through the whole
3 12 course of radiation, either during EBRT or at the end of the whole radiation treatment (Phase 1 and 2), as the gap between the EBRT and brachytherapy was one week or less in most of cases, so the contribution of the toxicities to which modality could not be clearly identified. Also, the same was applied to the radiation and chemotherapy toxicities. The toxicities reported might have been due to one of the two modalities or both, so identification of which toxicity belonged directly to any modality was difficult to determine precisely (the separation of radiation from chemotherapy toxicities can not be identified separately due to the use of the concomitant chemoradiation treatment). Patients were referred for definitive surgery (either APR or LAR) 4 weeks after the completion of neoadjuvant chemoradiation therapy. Histopathological assessment of response to neoadjuvant radiation and chemotherapy was performed. Complete pathological response (pcr) referred to complete clearance of tumor cells from the resection specimen; the presence of residual tumor cells in resection specimen was referred to as pathological partial response (ppr). No response means no change from the pretreatment view [15]. Follow-up after surgery was done as clinical evaluation (both general physical assessment and rectal examination) every 3 months for the first 2 years. Proctosigmoidoscpy was done on a yearly basis; however, if local symptoms occurred (i.e. progressive constipation or bleeding), an immediate proctosigmoidoscopy was done. Radiological evaluation (CT scan chest abdomen and pelvis; and bone scan) were requested if patient got symptomatic. Statistical analysis: Was done using the SPSS software, and descriptive statistics were used for patient criteria evaluation. The prognostic significance of different variables was assessed regarding its influence on the response rate using the Cross Tabulation Test. RESULTS Seventeen patients with histopathological diagnosis of rectal cancer had been identified and were referred for neoadjuvant chemoradiation therapy at the department of radiation oncology, King Abdul-Aziz University Hospital, Jeddah, Kingdom of Saudi Arabia, during the Mohamed E. El-Sayed & Zeinab H. El-Taher period from May 2006 to June 2007 (inclusive). Their ages ranged from 35 to 72 years (mean 57.4±11.6 years). Clinical and pathological features of patients involved in the study are shown in table (1). The mean duration of treatment for all patients with radiation therapy (EBRT+BT) was 6.7 weeks (±0.75 weeks). The mean follow-up period was.2 months, with Standard Error of the Mean (SEM) 2.91; (95% Confidence Interval; CI: ) with a range from 1.5 to 39 months, while the median follow-up was 9 months with SEM 1.37 (95% CI: ). Due to the short follow-up period, analysis of the disease free survival and overall survival is sub optimal (needs longer follow-up), while our aim was to focus on assessment of the pathological response and toxicity profile. Assessment of radiation toxicity was done as per RTOG toxicity criteria [] and is shown in table (2). All patients had low anterior resection (LAR). Only 2 patients (12%) developed wound infection one to two months following the operation, which healed spontaneously with medical treatment. One patient developed a stricture with partial intestinal obstruction one year after the operation and was treated conservatively with no further surgical interference. The pathological response rate was complete response (pcr) in 8 patients (47%), partial response (ppr) in 9 patients (53%). Complete clinical response rate ( ccr) before surgery was founded in 3 patients (18%) and clinical partial response (cpr) in patients (82%). The toxicity profile included proctitis grade III which developed in one patient (6%), dermatitis grade III in 2 patients (12%), while no patients developed grade III cystitis Table (2). Three patients (18%) developed grade III nausea and/or vomiting, 2 patients (12%) developed grade III diarrhea Table (3). Comparing the pathological response rate with other clinical and pathological variables revealed that there was no correlation between the pathological CR and overall duration of radiation therapy in weeks (p=0.25), T stage (p=0.68), or N stage p=0.41).
4 Prospective Phase II Study of Brachytherapy Boost 13 Fig. (1): Components of the rectal set. Fig. (5): The rectal cylinder in its final shape before its use. Fig. (2): Components of the rectal cylinder with quarter shield part on it. Fig. (6): The rectal applicator connected to HDR machine. Table (1): Clinical and pathological features of patients in the study. Fig. (3): Components of the rectal set cylinder with quarter shield on part of it (another view). Fig. (4): The rectal cylinder after fixation of its parts the cylinder (left) and the tandum (right). Feature Number Percentage (%) Sex: Male Female Histopathological grade (G): G1 G2 G Tumor (T) stage: T3 T Lymph node (N) stage: N0 N Distance from the anal verge: Less than 5 cm More than 5 cm
5 Table (2): Radiation toxicity profile of the patients in the study. Toxicity feature Proctitis Dermatitis Cystitis Grade (64%) Number (percentage) Grade 1 7 (41%) DISCUSSION Grade 2 9 (53%) Grade 3 1 (6%) 2 (12%) Table (3): Chemotherapy toxicity profile of the patients in the study. Toxicity feature Nausea and/or vomiting Diarrhea Grade 0 0 Number (percentage) Grade 1 10 (58%) Grade 2 4 (24%) There is much debate regarding the relative merits and disadvantages of adjuvant versus neoadjuvant combined modality therapy in the treatment of patients with non metastatic rectal carcinoma. Three randomized trials have directly compared the two approaches [16], and in all of them the overall survival was not different in the two approaches; however, the rate of sphincter preservation and local disease control were higher among the neoadjuvant combined modality approach. In phase II studies of neoadjuvant chemoradiation therapy in locally advanced rectal cancer, the rates of complete pathological response were higher following preoperative 5 FU-based chemoradiotherapy than they were in series using radiation therapy alone [17-26]. The standard neoadjuvant chemoradiation therapy is based on 5 FU-Leucovorin concomitant with pelvic irradiation aiming at 50.4 Gy/ 28 fractions/5.5 weeks. A lot of different techniques were developed to compare this standard approach against different radiation therapy protocols. In a Polish randomized trial involving 316 patients with T3-4 rectal cancer [27], patients were randomized between the standard radiation therapy and concomitant 5FU Leucovorin arm and a short course of high dose per fraction of 0 Grade 3 2 (12%) Mohamed E. El-Sayed & Zeinab H. El-Taher radiation RT (5 x 5 Gy) followed by surgery. In an early report, the pathological response rate was significantly higher in the chemoradiotherapy group (16 versus 1 percent), and there were fewer cases of radial margin positivity (4 versus 13 percent), but the rate of sphincter preservation in both groups was comparable (58 and 61 percent, respectively). Toxicity was much higher in the short course high dose per fraction arm. Local failure and survival rates were not reported. In the current trial, we studied in a prospective way a new technique in the preoperative chemoradiation therapy for rectal cancer in which the standard chemoradiation therapy was followed by a rectal brachytherapy boost, whereby phase I 4500cGy/25 fractions/5 weeks was given as an external beam irradiation followed by a brachytherapy boost to the rectum aiming at 800cGy in 2 fractions given by a high dose rate brachytherapy iridium 192 source. The clinical and pathological response rates, together with the toxicity profile were assessed. After completion of the study, it was found that the pathological response rate was complete response (pcr) in 8 patients (47%), pathological partial response (ppr) in 9 patients (53%). Complete clinical response rate (ccr) before surgery was founded in 3 patients (18%) and clinical partial response (cpr) in patients (82%). This emphasizes the superiority and more accuracy of the pathological assessment in this setting. The toxicity profile showed that grade III radiation proctitis was seen in one patient (6%); grade III dermatitis in 2 (12%), while no patients had grade III cystitis. As regards chemotherapy toxicity, 3 patients (18%) developed grade III nausea and/or vomiting, 2 patients (12%) developed grade III diarrhea. There is no much data about the use of brachytherapy as a boost to the external beam radiation therapy in the neoadjuvant setting in rectal cancer in the literatures. The biggest trial about brachytherapy in rectal cancer had been done in Canada by Vuong et al. [28], whereby forty-nine patients underwent staging with endoscopic endorectal ultrasound, and the tumor dimensions were determined with MRI of the pelvis. Patients with resectable rectal cancer (stages T2, T3, or early T4) were treated with
6 Prospective Phase II Study of Brachytherapy Boost preoperative high-dose-rate endorectal brachytherapy concomitant with the standard 5FU- Leucovorin chemotherapy followed by surgery 6-8 weeks later. The treatment planning was done with the use of a CT simulator, and the treatment was delivered using a flexible endorectal applicator with eight catheters arranged around the circumference of the applicator and a high-dose-rate brachytherapy remote afterloading system with an Iridium- 192 source. Digitally reconstructed radiographs were used as references for daily treatment. A tumor dose of 26 Gy in four fractions was prescribed. Fortynine patients received planned treatment, and all but 2 patients underwent planned surgery. The pathology specimens showed a complete macroscopic response in 64% of the patients and tumor downstaging in 67% of the patients. This study showed the impact of preoperative brachytherapy on gross tumor control but not on microscopic remission as in the current study. Conclusion: The use of brachytherapy as a boost to external beam radiation with concomitant chemotherapy in patients with locally advanced rectal cancer is an effective modality in terms of pathological complete response rate with an acceptable toxicity profile. The significance of this modality in terms of disease- free and overall survival was not clear in this study. So, it is recommended to do similar studies on a larger number of patients with longer followup periods to have more solid data. REFERENCES 1- Cancer Incidence Report, Saudi Arabia. Kingdom of Saudi Arabia, Ministry of Health, Saudi Cancer Society; Riyadh, published April 2008; Part II; Overview of Cancer incidence. 2004, p Allal AS, Bieri S, Pelloni A, Spataro V, Anchisi S, Ambrosetti P, et al. Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers: feasibility, oncologic results and quality of life outcomes. Br J Cancer. 2000, 82 (6): Rider WD, Palmer JA, Mahoney LJ, Robertson CT. Preoperative irradiation in operable cancer of the rectum: report of the Toronto trial. Can J Surg. 1977, 20 (4): Gérard A, Buyse M, Nordlinger B, Loygue J, Pène F, Kempf P, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg. 1988, 208 (5): Wagman R, Minsky BD, Cohen AM, Guillem JG, Paty PP. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys. 1998, 42 (1): Rouanet P, Saint-Aubert B, Lemanski C, Senesse P, Gourgou S, Quenet F, et al. Restorative and nonrestorative surgery for low rectal cancer after high-dose radiation: long-term oncologic and functional results. Dis Colon Rectum. 2002, 45 (3): Hyams DM, Mamounas EP, Petrelli N, Rockette H, Jones J, Wieand HS, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum. 1997, 40 (2): Kuvshinoff B, Maghfoor I, Miedema B, Bryer M, Westgate S, Wilkes J, et al. Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas: are < or = 1 cm distal margins sufficient?. Ann Surg Oncol. 2001, 8 (2): Valentini V, Coco C, Cellini N, Picciocchi A, Genovesi D, Mantini G, et al. Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys. 1998, 40 (5): Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999, 17 (8): Grann A, Feng C, Wong D, Saltz L, Paty PP, Guillem JG, et al. Preoperative combined modality therapy for clinically resectable T3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2001, 49 (4): Gambacorta MA, Valentini V, Morganti AG, Mantini G, Miccichè F, Ratto C, et al. Chemoradiation with raltitrexed (Tomudex) in preoperative treatment of stage II-III resectable rectal cancer: a phase II study. Int J Radiat Oncol Biol Phys. 2004, 60 (1): Rengan R, Paty P, Wong WD, Guillem J, Weiser M, Temple L, et al. Distal ct2n0 rectal cancer: is there an alternative to abdominoperineal resection?. J Clin Oncol. 2005, 23 (22): http// Radiation Therapy Oncology Group (RTOG): National Cancer Institute; Cancer Therapy Evaluation Program; Common Toxicity Criteria manual June 1, 1999; version 2. Avilable. 15- Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005, 47 (2): Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum. 1993, 36 (6):
7 16 Mohamed E. El-Sayed & Zeinab H. El-Taher 17- Mendenhall WM, Bland KI, Copeland EM 3 rd, Summers GE, Pfaff WW, Souba WW, et al. Does preoperative radiation therapy enhance the probability of local control and survival in high-risk distal rectal cancer?. Ann Surg. 1992, 215 (6): Myerson RJ, Michalski JM, King ML, Birnbaum E, Fleshman J, Fry R, et al. Adjuvant radiation therapy for rectal carcinoma: predictors of outcome. Int J Radiat Oncol Biol Phys. 1995, 32 (1): Chari RS, Tyler DS, Anscher MS, Russell L, Clary BM, Hathorn J, et al. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg. 1995, 221 (6): ; discussion Minsky BD, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Reichman B, et al. Enhancement of radiationinduced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol. 1992, 10 (1): Minsky BD, Cohen AM, Enker WE, Paty P. Sphincter preservation with preoperative radiation therapy and coloanal anastomosis. Int J Radiat Oncol Biol Phys. 1995, 31 (3): Ngan SY, Burmeister BH, Fisher R, Rischin D, Schache DJ, Kneebone A, et al. Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2001, 50 (4): Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol. 2001, 24 (2): Bosset JF, Magnin V, Maingon P, Mantion G, Pelissier EP, Mercier M, et al. Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial, Int J Radiat Oncol Biol Phys. 2000, 46 (2): Rich TA, Skibber JM, Ajani JA, Buchholz DJ, Cleary KR, Dubrow RA, et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys. 1995, 32 (4): Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2002, 54 (2): Mehta VK, Cho C, Ford JM, Jambalos C, Poen J, Koong A, et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys. 2003, 55 (1): Vuong T, Devic S, Moftah B, Evans M, Podgorsak EB. High-dose-rate endorectal brachytherapy in the treatment of locally advanced rectal carcinoma: technical aspects. Brachytherapy. 2005, l4 (3):
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 6, NUMBER 2, SPRING 2005
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 6, NUMBER 2, SPRING 2005 Advantages of inflatable multichannel endorectal applicator in the neo-adjuvant treatment of patients with locally advanced
More informationMini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationDepartment of Radiotherapy, Pt. BDS PGIMS, Rohtak, Haryana, India
Bharti et al., IJPSR, 2010; Vol. 1 (11): 169-173 ISSN: 0975-8232 IJPSR (2010), Vol. 1, Issue 11 (Research Article) Received on 29 September, 2010; received in revised form 21 October, 2010; accepted 26
More informationPre-operative Chemoradiotherapy with Oral Capecitabine in Locally Advanced, Resectable Rectal Cancer
Pre-operative Chemoradiotherapy with Oral Capecitabine in Locally Advanced, Resectable Rectal Cancer DIMITRIS P. KORKOLIS 1, CHRISTOS S. BOSKOS 2, GEORGE D. PLATANIOTIS 1, EMMANUEL GONTIKAKIS 1, IOANNIS
More informationDistal Margin Requirements After Preoperative Chemoradiotherapy for Distal Rectal Carcinomas: Are 1cm Distal Margins Sufficient?
Annals of Surgical Oncology, 8(2):163 169 Published by Lippincott Williams & Wilkins 2001 The Society of Surgical Oncology, Inc. Distal Margin Requirements After Preoperative Chemoradiotherapy for Distal
More informationChemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer Emily Chan, Qian Shi, Julio Garcia-Aguilar, Peter Cataldo, Jorge
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationRadiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology
Radiotherapy for rectal cancer Karin Haustermans Department of Radiation Oncology O U T L I N E RT with TME surgery? Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection
More informationRe-irradiation in recurrent rectal cancer: single institution experience
Original Article Re-irradiation in recurrent rectal cancer: single institution experience Rasha Mohammad Abdel Latif, Ghada E. El-Adawei, Wael El-Sada Clinical Oncology & Nuclear Medicine Department, Mansoura
More informationRadiotherapy Physics and Equipment
Radiological Sciences Department Radiotherapy Physics and Equipment RAD 481 Lecture s Title: Introduction Dr. Mohammed EMAM Ph.D., Paris-Sud 11 University Vision :IMC aspires to be a leader in applied
More informationPreoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer
Evidence-Based Series 2-4 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Preoperative or Postoperative Therapy for the Management of Patients with
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationPreoperative adjuvant radiotherapy
Preoperative adjuvant radiotherapy Dr John Hay Radiation Oncology Program BC Cancer Agency Vancouver Cancer Centre The key question for the surgeon Do you think that this tumour can be resected with clear
More informationPreoperative capecitabine and pelvic radiation in locally advanced rectal cancer: preliminary results (Mansoura experience)
Original Article Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer: preliminary results (Mansoura experience) Abeer Hussien Anter 1, Ghada Ezzat Eladawei 2, Mahmoud Mosbah
More informationNeoadjuvant therapy of rectal carcinoma with UFT leucovorin plus radiotherapy
Original article Annals of Oncology 13: 730 736, 2002 DOI: 10.1093/annonc/mdf116 Neoadjuvant therapy of rectal carcinoma with UFT leucovorin plus radiotherapy J. Feliu 1 *, J. Calvillo 2, A. Escribano
More informationRectal Cancer. Madhulika G. Varma MD Associate Professor and Chief Section of Colorectal Surgery University of California, San Francisco
Rectal Cancer Madhulika G. Varma MD Associate Professor and Chief Section of Colorectal Surgery University of California, San Francisco Modern Treatment for Rectal Cancer Improve Local Control Improved
More informationHistologic response after neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma: experience from Sudan.
Histologic response after neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma: experience from Sudan. Ahmed Abd Elrahman Abdalla 1, Awad Ali M. Alawad 2, Hussein Abdalla M. Ali 3 1.
More informationRECTAL CANCER CLINICAL CASE PRESENTATION
RECTAL CANCER CLINICAL CASE PRESENTATION Francesco Sclafani Medical Oncologist, Clinical Research Fellow The Royal Marsden NHS Foundation Trust, London, UK esmo.org Disclosure I have nothing to declare
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of preoperative high dose rate brachytherapy for rectal cancer Rectal cancer is a
More informationCombined Modality Treatment of Anal Carcinoma
Combined Modality Treatment of Anal Carcinoma F. ROELOFSEN, a H. BARTELINK b a Bethesda Krankenhaus, Essen, Germany; b The Netherlands Cancer Institute/Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, The
More informationRectal Cancer. GI Practice Guideline
Rectal Cancer GI Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Dr. Francisco Perera MD, FRCPC (Radiation Oncologist) Dr. Jay Engel MD, FRCPC (Surgical Oncologist) Approval Date: 2006 This guideline
More informationNeoadjuvant Therapy for Rectal Cancer is Overrated. Joon H. Lee, Research Resident University of Colorado 8/31/2009
Neoadjuvant Therapy for Rectal Cancer is Overrated Joon H. Lee, Research Resident University of Colorado 8/31/2009 Objectives Brief overview of staging rectal cancer Current guidelines for evaluation and
More informationCREATE Trial Proposal: Survey of current practice and potential trial participation
CREATE Trial Proposal: Survey of current practice and potential trial participation Approximately a quarter of newly diagnosed rectal cancer patients have features on pre-treatment pelvic MRI indicating
More informationLong Term Outcomes of Preoperative versus
RESEARCH ARTICLE Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand Pichayada Darunikorn
More information11/21/13 CEA: 1.7 WNL
Case Scenario 1 A 70 year-old white male presented to his primary care physician with a recent history of rectal bleeding. He was referred for imaging and a colonoscopy and was found to have adenocarcinoma.
More informationEvaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant Therapy of Locally Advanced Rectal Cancer
Efficacy of Modified De Gramont and FOLFOX4 Regimens for Locally Advanced Rectal Cancer RESEARCH COMMUNICATION Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant
More informationRadiotherapy for Rectal Cancer. Kevin Palumbo Adelaide Radiotherapy Centre
Radiotherapy for Rectal Cancer Kevin Palumbo Adelaide Radiotherapy Centre Overview CRC are common (3 rd commonest cancer) rectal Ca approx 25-30% of all CRC. Presentation PR bleeding: beware attributing
More informationRectal Cancer: Classic Hits
Rectal Cancer: Classic Hits Charles M. Friel, MD Associate Professor of Surgery Section of Colon and Rectal Surgery University of Virginia September 28, 2016 None Disclosures 1 Objectives Review the Classic
More informationHagit Tulchinsky, MD, 1,2 Einat Shmueli, MD, 3 Arie Figer, MD, 3 Joseph M. Klausner, MD, 2 and Micha Rabau, MD 1,2
Annals of Surgical Oncology DOI: 10.1245/s10434-008-9892-3 An Interval [7 Weeks between Neoadjuvant Therapy and Surgery Improves Pathologic Complete Response and Disease Free Survival in Patients with
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year
More informationNordic Society for Gynecological Oncology Advisory Board of Radiotherapy
Nordic Society for Gynecological Oncology Advisory Board of Radiotherapy Guidelines for postoperative irradiation of cervical cancer Contents: 1. Treatment planning for EBRT. 2 2. Target definition for
More informationAdjuvant Therapy for Rectal Cancer: Results and Controversies
Review Article [1] August 01, 1998 Gastrointestinal Cancer [2], Colorectal Cancer [3] By Bruce D. Minsky, MD [4] During the past decade, advances have been made in the adjuvant treatment of resectable
More informationTrimodality Therapy for Muscle Invasive Bladder Cancer
Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,
More informationBackground: Patients and methods: Results: Conclusions:
Chapter 7 7 Results of European pooled analysis of IORT containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastase
More informationA Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer
A Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer Tony Kin Ming Lam Radiation Planner Dr Patricia Lindsay, Radiation Physicist Dr John Kim, Radiation Oncologist Dr Kim Ann Ung,
More informationOriginal article. xx xx x xx x
xx xx x xx x Neoadjuvant chemoradiotherapy plus adjuvant chemotherapy versus adjuvant chemoradiotherapy in the treatment of patients ANNALS with resectable OF rectal GASTROENTEROLOGY adenocarcinoma: a
More informationColorectal Cancer Treatment
Scan for mobile link. Colorectal Cancer Treatment Colorectal cancer overview Colorectal cancer, also called large bowel cancer, is the term used to describe malignant tumors found in the colon and rectum.
More informationGYNECOLOGIC CANCER and RADIATION THERAPY. Jon Anders M.D. Radiation Oncology
GYNECOLOGIC CANCER and RADIATION THERAPY Jon Anders M.D. Radiation Oncology Brachytherapy Comes from the Greek brakhus meaning short Brachytherapy is treatment at short distance Intracavitary vs interstitial
More informationCase Report 17-Week Delay Surgery after Chemoradiation in Rectal Cancer with Complete Pathological Response
Case Reports in Surgery Volume 2015, Article ID 816491, 5 pages http://dx.doi.org/10.1155/2015/816491 Case Report 17-Week Delay Surgery after Chemoradiation in Rectal Cancer with Complete Pathological
More informationDisclosure. Acknowledgement. What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Rectal cancer imaging. None
What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Zhen Jane Wang, MD Assistant Professor in Residence UC SF Department of Radiology Disclosure None Acknowledgement Hueylan Chern, MD, Department
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationRectal Cancer Update 2008 The Last 5 cm. Consensus Building
Rectal Cancer Update 2008 The Last 5 cm Consensus Building Case Distal Rectal Cancer 65 male physician Rectal mass: 5cm from anal verge, 1cm above sphincter? Imaging choice: CT vs MR vs ERUS? Adjuvant
More informationCarcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationRADIATION THERAPY WITH ONCE-WEEKLY GEMCITABINE IN PANCREATIC CANCER: CURRENT STATUS OF CLINICAL TRIALS
doi:10.1016/s0360-3016(03)00449-8 Int. J. Radiation Oncology Biol. Phys., Vol. 56, No. 4, Supplement, pp. 10 15, 2003 Copyright 2003 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/03/$
More informationIndex. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,
More informationCase Scenario year-old white male presented to personal physician with dyspepsia with reflux.
Case Scenario 1 57-year-old white male presented to personal physician with dyspepsia with reflux. 7/12 EGD: In the gastroesophageal junction we found an exophytic tumor. The tumor occupies approximately
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationWorld Journal of Colorectal Surgery
World Journal of Colorectal Surgery Volume 3, Issue 4 2013 Article 3 Sigmoidorectal Intussusception Presenting as Prolapse Per Anus in an Adult Venugopal Hg Hasmukh B. Vora Mahendra S. Bhavsar SMT.NHL
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationis time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the
My name is Barry Feig. I am a Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. I am going to talk to you today about the role for surgery in the treatment
More informationStaging Colorectal Cancer
Staging Colorectal Cancer CT is recommended as the initial staging scan for colorectal cancer to assess local extent of the disease and to look for metastases to the liver and/or lung Further imaging for
More informationShort course radiation therapy for rectal cancer in the elderly: can radical surgery be avoided?
Short communication Short course radiation therapy for rectal cancer in the elderly: can radical surgery be avoided? Michael A. Cummings 1, Kenneth Y. Usuki 1, Fergal J. Fleming 2, Mohamedtaki A. Tejani
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More information8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank
Quiz 1 Overview 1. Beginning with the cecum, which is the correct sequence of colon subsites? a. Cecum, ascending, splenic flexure, transverse, hepatic flexure, descending, sigmoid. b. Cecum, ascending,
More informationTreatment of Locally Advanced Rectal Cancer: Current Concepts
Treatment of Locally Advanced Rectal Cancer: Current Concepts James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationPelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer
Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer Esten S. Nakken MD PhD Division of Cancer Medicine Oslo University Hospital
More informationOpportunity for palliative care Research
Opportunity for palliative care Research Role of Radiotherapy in Multidisciplinary Management of Rectal Cancers Dr Sushmita Pathy Associate Professor Department of Radiation Oncology Dr BRA Institute Rotary
More informationPORTEC-4. Patient seqnr. Age at inclusion (years) Hospital:
May 2016 Randomisation Checklist Form 1, page 1 of 2 Patient seqnr. Age at inclusion (years) Hospital: Eligible patients should be registered and randomised via the Internet at : https://prod.tenalea.net/fs4/dm/delogin.aspx?refererpath=dehome.aspx
More informationNCCN Guidelines for Hepatobiliary Cancers V Web teleconference on 10/24/17
Guideline Page and Request HCC-4 the American Society of Radiation Oncology (ASTRO): We recommend further clarification of the eligibility criteria for surgical resection and liver transplantation, respectively.
More informationFirst, how does radiation work?
Hello, I am Prajnan Das, Faculty Member in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center. We are going to talk today about some of the basic principles regarding
More informationIntraoperative Radiation Therapy for
Frontiers ofradiation Therapy and Oncology Reprint Editors: J.M. Vaeth, J.L. Meyer, San Francisco, Calif. ~' Publishers: S.Karger, Basel Printed in Switzerland Vaeth JM, Meyer JL (eds): The Role of High
More informationA Case of Marked Response to Preoperative Chemoradiotherapy for Rectal Cancer With Para-Aortic Lymph Node Metastasis
Int Surg 2011;96:139 143 Case Report A Case of Marked Response to Preoperative Chemoradiotherapy for Rectal Cancer With Para-Aortic Lymph Node Metastasis Atsushi Horiuchi, Keiji Matsuda, Takuya Akahane,
More information20 Prostate Cancer Dan Ash
20 Prostate Cancer Dan Ash 1 Introduction Prostate cancer is a disease of ageing men for which the aetiology remains unknown. The incidence rises up to 30 to 40% in men over 80. The symptoms of localised
More informationEarly Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh
Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh What is Early rectal cancer? pt1t2n0m0 Predictors for LN involvement Size Depth Intramural
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationCOLON AND RECTAL CANCER
COLON AND RECTAL CANCER Mark Sun, MD Clinical Associate Professor of Surgery University of Minnesota No disclosures Objectives 1) Understand the epidemiology, management, and prognosis of colon and rectal
More informationCurrent Status of Adjuvant Therapy for Colorectal Cancer
Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationCOLORECTAL CANCER STAGING in 2010
COLORECTAL CANCER STAGING in 2010 Robert A. Halvorsen, MD, FACR MCV Hospitals / VCU Medical Center Richmond, Virginia I do not have any relevant financial relationships with any commercial interests COLON
More informationTreatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
More informationCOX-2 inhibitor and irradiation. Saitama Cancer Center Kunihiko Kobayashi MD, PhD
COX-2 inhibitor and irradiation Saitama Cancer Center Kunihiko Kobayashi MD, PhD Synthesis of prostaglandins from arachidonic acid by cyclooxygenase (COX) enzymes JNCI 95:1440, 2003 Difference between
More informationPROCARE FINAL FEEDBACK Definitions
1 PROCARE FINAL FEEDBACK 2006-2014 Definitions Version 0.2 29/10/2015 2 Table of Contents Introduction... 3 Part 1: PROCARE indicators 2006-2014... 4 1.1. Methods... 4 1.1.1. Descriptive numbers... 4 1.1.2.
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationCT PET SCANNING for GIT Malignancies A clinician s perspective
CT PET SCANNING for GIT Malignancies A clinician s perspective Damon Bizos Head, Surgical Gastroenterology Charlotte Maxeke Johannesburg Academic Hospital Case presentation 54 year old with recent onset
More informationBCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy
BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GIRCRT Gastrointestinal
More informationDefinitions. Brachytherapy in treatment of cancer. Implantation Techniques and Methods of Dose Specifications. Importance of Brachytherapy in GYN
Implantation Techniques and Methods of Dose Specifications Brachytherapy Course Lecture V Krishna Reddy, MD, PhD Assistant Professor, Radiation Oncology Brachytherapy in treatment of cancer GYN Cervical
More informationProtocol of Radiotherapy for Breast Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Breast Cancer Indication of radiotherapy Indications for Post-Mastectomy Radiotherapy (1) Axillary lymph node 4 positive (2) Axillary lymph node 1-3 positive:
More informationhttps://patient.varian.com/sit es/default/files/videos/origin al/imrt.mp4 brachy- from Greek brakhys "short" Historically LDR has been used. Cs-137 at 0.4-0.8 Gy/h With optimally placed device, dose
More informationRisk factors for impaired healing of the perineal wound after abdominoperineal resection of rectum for carcinoma
Original article doi:10.1111/j.1463-1318.2006.01159.x Risk factors for impaired healing of the perineal wound after abdominoperineal resection of rectum for carcinoma D. Y. Artioukh, R. A. Smith and K.
More informationCase Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.
Case Scenario 1 July 10, 2010 A 67-year-old male with squamous cell carcinoma of the mid thoracic esophagus presents for surgical resection. The patient has completed preoperative chemoradiation. This
More informationANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto)
ANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Lee-Ying (Staff Medical Oncologist, University of Calgary), Dr. Kzyzanowska (Staff
More informationCOLON AND RECTAL CANCER
No disclosures COLON AND RECTAL CANCER Mark Sun, MD Clinical Assistant Professor of Surgery University of Minnesota Colon and Rectal Cancer Statistics Overall Incidence 2016 134,490 new cases 8.0% of all
More informationCase Scenario 1. History
History Case Scenario 1 A 53 year old white female presented to her primary care physician with post-menopausal vaginal bleeding. The patient is not a smoker and does not use alcohol. She has no family
More informationChemoradiation - an overview and examples (adapted from issues of JOC Bulletin, Joint Oncology Conference)
Chemoradiation - an overview and examples (adapted from issues of JOC Bulletin, Joint Oncology Conference) Chemoradiation for Carcinoma of the Cervix Dr. William Foo Chemoradiation became the standard
More information3D ANATOMY-BASED PLANNING OPTIMIZATION FOR HDR BRACHYTHERAPY OF CERVIX CANCER
SAUDI JOURNAL OF OBSTETRICS AND GYNECOLOGY VOLUME 11 NO. 2 1430 H - 2009 G 3D ANATOMY-BASED PLANNING OPTIMIZATION FOR HDR BRACHYTHERAPY OF CERVIX CANCER DR YASIR BAHADUR 1, DR CAMELIA CONSTANTINESCU 2,
More informationEndobronchial High Dose Rate Brachytherapy for Control of NSCLC
Journal of the Egyptian Nat. Cancer Inst., Vol., No. 3, September: 215-221, 2001 Endobronchial High Dose Rate Brachytherapy for Control of NSCLC SEDKY L., M.D.; KAMAL K.A., M.D.; KASENTER A.G., M.S. and
More informationChapter 6. Ann Surg 2007; 246: 83-90
Chapter 6 Risk factors for adverse outcome in patients with rectal cancer treated with an abdominoperineal resection in the total mesorectal excision trial Marcel den Dulk, Corrie A.M. Marijnen, Hein Putter,
More informationCOLORECTAL CARCINOMA
QUICK REFERENCE FOR HEALTHCARE PROVIDERS MANAGEMENT OF COLORECTAL CARCINOMA Ministry of Health Malaysia Malaysian Society of Colorectal Surgeons Malaysian Society of Gastroenterology & Hepatology Malaysian
More informationSome Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer
Bladder Cancer Role of Radiation in Bladder Sparing David C. Beyer M.D., FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Primary Radiation for Bladder Cancer No modern surgery / XRT randomized
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationWait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study
/, Vol. 6, No. 39 Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study Jun Li 1, Hao Liu 2, Jie Yin 3, Sai Liu
More informationSphincter preservation in distal CT2N0 rectal cancer after preoperative chemoradiotherapy
Wasserberg et al. Radiation Oncology 2014, 9:233 RESEARCH Open Access Sphincter preservation in distal CT2N0 rectal cancer after preoperative chemoradiotherapy Nir Wasserberg 1*, Yulia Kundel 2,3, Ofer
More informationRECTAL CANCER: Adjuvant Therapy. Maury Rosenstein, MD Montefiore Medical Center December 2012
RECTAL CANCER: Adjuvant Therapy Maury Rosenstein, MD Montefiore Medical Center December 2012 Overview Indications for adjuvant therapy Preoperative Postoperative New Advances Epidemiology Approximately
More informationColorectal Pathway Board (Clinical Subgroup): Imaging Guidelines September 2015
Colorectal Pathway Board (Clinical Subgroup): Imaging Guidelines September 2015 1 Contents Page No. 1. Objective 3 2. Imaging Techniques 3 3. Staging of Colorectal Cancer 5 4. Radiological Reporting 6
More informationClinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience
Original Article Clinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience Rachel Murray 1, Fantine Giap 2, Ray Lin
More information